Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study

被引：0
|
作者：
Finkel, Richard
Mercuri, Eugenio
Kirschner, Jan
Chiriboga, Claudia A.
Kuntz, Nancy
Darras, Basil T.
Shieh, Perry B.
Saito, Kayoko
De Vivo, Darryl
Day, John W.
Mazzone, Elena S.
Montes, Jacqueline
Yang, Qingqing
Zhong, Zhenshao John
Gheuens, Sarah
Bennett, C. Frank
Schneider, Eugene
Farwell, Wildon
机构：
来源：
NEUROLOGY | 2017年 / 89卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E100 / E101
页数：2
相关论文
共 50 条
  • [31] Baseline Characteristics and Interim Safety in RESPOND: A Phase 4 Study in Children with Spinal Muscular Atrophy (SMA) Treated With Nusinersen After Onasemnogene Abeparvovec
    Kuntz, Nancy
    Parsons, Julie
    Brandsema, John F.
    Proud, Crystal
    Finkel, Richard
    Swoboda, Kathryn
    Masson, Ricardo
    Liu, Yingying
    Makepeace, Corinne
    Paradis, Angela
    Berger, Zdenek
    Somera-Molina, Kathleen
    NEUROLOGY, 2023, 100 (17)
  • [32] Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
    Santiago Zuluaga-Sanchez
    Megan Teynor
    Christopher Knight
    Robin Thompson
    Thomas Lundqvist
    Mats Ekelund
    Annabelle Forsmark
    Adrian D. Vickers
    Andrew Lloyd
    PharmacoEconomics, 2019, 37 : 845 - 865
  • [33] A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): An Introduction
    Place, A.
    Barrett, D.
    Cote, S.
    Iarrobino, R.
    Nomikos, G.
    Yung, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 170 - 170
  • [34] A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): An Introduction
    Place, Amy
    NEUROLOGY, 2020, 94 (15)
  • [35] Interim results from RESPOND: a study of nusinersen in children with spinal muscular atrophy (SMA) previously treated with onasemnogene abeparvovec (OA)
    Masson, R.
    Proud, C.
    Finkel, R.
    Parsons, J.
    Kuntz, N.
    Foster, R.
    Li, W.
    Chary, S.
    Sohn, J.
    Fradette, S.
    Youn, B.
    Paradis, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [36] A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): A Study Update
    Place, Amy
    Barrett, Doreen
    Nomikos, George
    Cote, Barrett
    Song, Guochen
    Iarrobino, Ryan
    Chyung, Yung
    NEUROLOGY, 2021, 96 (15)
  • [37] Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
    Acsadi, Gyula
    Crawford, Thomas O.
    Mueller-Felber, Wolfgang
    Shieh, Perry B.
    Richardson, Randal
    Natarajan, Niranjana
    Castro, Diana
    Ramirez-Schrempp, Daniela
    Gambino, Giulia
    Sun, Peng
    Farwell, Wildon
    MUSCLE & NERVE, 2021, 63 (05) : 668 - 677
  • [38] Motor unit number index in children with later-onset spinal muscular atrophy
    Verma, Sumit
    Forte, Jasmine
    Ritchey, Mary
    Shah, Durga
    MUSCLE & NERVE, 2020, 62 (05) : 633 - 637
  • [39] The alteration of left ventricular strain in later-onset spinal muscular atrophy children
    Cui, Yiqin
    Feng, Yijie
    Xia, Yu
    Fu, Xingpeng
    Gong, Ming
    Qian, Jingjing
    Yu, Jin
    Ye, Jingjing
    Gao, Feng
    Cheng, Hongqiang
    Mao, Shanshan
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2022, 16
  • [40] Longer-term Nusinersen Treatment According to Age at First Dose: Results From the SHINE Study in Later-onset Spinal Muscular Atrophy
    Mueller-Felber, W.
    Darras, B. T.
    Chiriboga, C. A.
    Farrar, M. A.
    Mercuri, E.
    Kirschner, J.
    Kuntz, N. L.
    Acsadi, G.
    Tulinius, M.
    Montes, J.
    Gambino, G.
    Foster, R.
    Ramirez-Schrempp, D.
    Wong, J.
    Kandinov, B.
    Farwell, W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 221 - 221
12345